Video

Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

Author(s):

Shaji K. Kumar, MD

In Partnership With:

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myeloma.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myelomacl-2 protein.

There are 2 studies looking at the efficacy of venetoclax in patients with multiple myeloma, explains Kumar. One study, which enrolled 66 patients, looked at venetoclax alone, where the maximum dose was determined as well as an overall response rate of 21% in the advanced relapsed patient population. The median progression-free survival for these patients was nearly 12 months.

Additional molecular testing has been done to identify the cohort of patients who are most likely to respond to venetoclax. This identified a group where the response rate was 85%, states Kumar.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Related Content
Metastatic Colorectal Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 14th 2025

Mayo Clinic Researchers Identify Proteins Linked to Immunotherapy Resistance in Metastatic Colorectal Cancer

Roxana S. Dronca, MD, professor, oncology, consultant, Division of Hematology/Oncology, Department of Internal Medicine, director, Mayo Clinic Comprehensive Cancer Center
January 20th 2025

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

Yousef Zakharia, MD, medical oncologist, vice chair, Genitourinary Malignancy Disease Group, Mayo Clinic Comprehensive Cancer Center; medical director, Experimental Therapeutics Clinic, Mayo Clinic
January 15th 2025

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Roxana S. Dronca, MD
January 13th 2025

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

Naseema Gangat, MBBS, of Mayo Clinic
January 13th 2025

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden